Traditional treatment regimens for adult acute lymphoblastic leukemia, including allogeneic hematopoietic cell transplantation, result in an overall survival of approximately 40%, a figure hardly comparable with the extraordinary 80% to 90% cure rate currently reported in children. When translated to the adult setting, modern pediatric-type regimens improve the survival to approximately 60% in young adults. The addition of tyrosine kinase inhibitors for patients with Philadelphia chromosome-positive disease and the measurement of minimal residual disease to guide risk stratification and postremission approaches has led to additional improvements in outcomes. Relapsed disease and treatment toxicity-sparing no patient but representing a major concern especially in the elderly-are the most critical current issues awaiting further therapeutic advancement. Recently, there has been considerable progress in understanding the disease biology, specifically the Philadelphia-like signature, as well as other high-risk subgroups. In addition, there are several new agents that will undoubtedly contribute to additional improvement in the current outcomes. The most promising agents are monoclonal antibodies, immunomodulators, and chimeric antigen receptor T cells, and, to a lesser extent, several new drugs targeting key molecular pathways involved in leukemic cell growth and proliferation. This review examines the evidence supporting the increasing role of the new therapeutic tools and treatment options in different disease subgroups, including frontline and relapsed or refractory disease. It is now possible to define the best individual approach on the basis of the emerging concepts of precision medicine.
INTRODUCTION
In Western countries, new cases of adult acute lymphoblastic leukemia (ALL) occur at an annual rate of approximately one per 100,000, with a bimodal distribution decreasing at age 45 to 54 years and increasing again in people older than 55 years, totaling approximately 2,300 new cases per year for patients older than 15 years (n = 1,750 between ages 15 and 55 years) in the United States.
1,2 Over the past decade, we have witnessed an incredible therapeutic improvement. Currently, pediatric patients have an estimated 5-year overall survival (OS) approaching 90%. [3] [4] [5] Modern pediatric programs thrive on an intensified use of corticosteroids (mainly dexamethasone), antimetabolites (especially methotrexate and 6-mercaptopurine) and L-asparaginase/ pegylated-asparaginase, and rely on minimal residual disease (MRD) analysis for additional dose intensification or allogeneic hematopoietic cell transplantation (HCT).
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RECENT ADVANCES USING PEDIATRIC REGIMENS IN ADULTS
The results in adult ALL, unfortunately, have not kept pace with those in pediatric ALL, with OS rates , 45% 9 despite the addition of CNS prophylaxis, late intensification with prolonged maintenance chemotherapy, and an extensive use of HCT in high-risk (HR) subsets. Currently, pediatric-inspired regimens are being administered in young adult patients, leading to improvements in event-free survival (EFS) and OS rates as compared with historical controls. [10] [11] [12] [13] This approach, initially reserved for adolescents and young adults (AYA; , 40 years old) 10, 14, 15 and later applied to patients up to 50 to 60 years of age, 11, 12, 16 has increased the 5-year OS rate to $ 50%, and up to 70% to 80% in favorable subsets (ie, AYA, standard risk, MRD negative; Appendix Table A1 , online only), 17 but not in older patients, whose survival decreases progressively to , 20%. [2] [3] [4] Finally, allogeneic HCT is Author affiliations and support information (if applicable) appear at the end of this article.
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often considered in first complete remission (CR) in adults with HR disease to reduce the risk of relapse, 18 but potential benefits may be offset by transplant-related morbidity and mortality, especially in the elderly. 19 
Risk Stratification
Current risk stratification criteria reflect the clinical and prognostic heterogeneity of ALL and determine which patients should undergo more intensive treatment including HCT, due to the high risk of relapse. Besides patient-related characteristics, namely advanced age and poor performance status, recognized risk factors include hyperleukocytosis, early thymic-precursor (ETP) phenotype and adverse cytogenetics or genetics (ie, t(9;22)/BCR-ABL1 rearrangement [Philadelphia chromosome positive (Ph+) ALL], Ph-like ALL, t(4;11)/KMT2A-AFF1 rearrangement, hypodiploidy, mutated TP53, and other abnormalities). 20 In all studies, MRD has proven to be a major independent risk factor for relapse. 21 In contrast to MRD-negative patients (typically defined as having ,10 24 residual leukemic cells in their CR marrow compared with baseline), MRD-positive patients are seldom cured with chemotherapy alone. In prospective trials performed over the past 25 years, enrolling . 1,500 patients, [22] [23] [24] OS was between 60% and 80% with chemotherapy alone in MRD-negative patients, even in HR subsets and Ph+ ALL. 25 Instead MRD-positive patients benefit partially from HCT, although with OS rates # 50% in intention-totreat analyses, due to the cumulative effects of pre-and posttransplantation relapse and transplant-related deaths.
26-28
Current Therapeutic Limitations
The treatment of older patients represents a major obstacle, 29 and, at all ages, relapse affects one-third or more of the patients and remains an unsolved issue due to extremely poor results with standard salvage chemotherapy. An international study of 1,706 patients with refractory or recurrent (R/R) B-cell precursor (BCP) ALL reported 3-year survival rates of only 10%. 30 Results are worse in Ph+ ALL 31 and T-cell precursor (TCP) ALL, with some mitigation provided by nelarabine. 32 Another concern is high-grade toxicity causing death in remission, which increases with age and with transplants ($ 20% in most studies).
The Challenge of New Management Options
Despite these constraints, the management of adult ALL can be improved. This new era started with the advent of tyrosine kinase inhibitors (TKI) for Ph+ ALL, 33 flourished with immunotherapy for BCP ALL and is now empowered by novel immunotherapeutics (Tables 1 and 2) 13,34-64 and several small molecules targeting critical metabolic pathways (Fig 1; Tables 3 and 4) , used alone or in combination in specific ALL subsets (Fig 2) . More robust data on toxicity, dosing, and therapeutic implications are required and will be generated by ongoing trials (Appendix Tables A2-A7, online  only) ; however, some of these agents could improve the cure rate and prompt a shift in the therapeutic regimens for ALL. The most promising agents currently available are those targeting cell membrane antigens (namely, CD19, CD20, and CD22) and major molecular pathways controlling cell proliferation and apoptotic response (ie, multiple kinases and members of Bcl-2, TP53, RAS, mTOR/PI3K, pre-B/B-cell receptor, and NOTCH networks). Furthermore, new molecular and drug profiling techniques might become essential to define targets and compounds deserving evaluation in trials or individual patients. This new strategy is still largely speculative, especially in frontline therapy, because molecular sequencing and new drug-sensitivity screening models have not yet been sufficiently tested or validated in early clinical trials. This review focuses on the rationale supporting this change and illustrates how new treatment approaches and related experimental work are likely to modify and improve the management of adult ALL.
ACTIONABLE TARGET AND DRUG SCREENING
Molecular Profiling
Although targets for immunotherapy can be identified by diagnostic immunophenotype, ALL subtype classification and target identification rely mostly on molecular genetics for the detection of gene rearrangements, translocations, and actionable recurrent mutations with genome-wide technologies. [65] [66] [67] [68] [69] In the era of precision medicine, molecular profiling has gained in importance for the management of this disease. New concepts for targeted therapies and combinatory approaches with immunotherapy and/or chemotherapy require sophisticated experimental modeling and are now increasingly entering clinical development (Fig 2; Appendix Tables A2-A10) .
Drug Profiling Platforms
Because the molecular classification of ALL is often insufficient to capture the complex biology of the disease and provide a predictive guide for treatment, 70 functional screening approaches are being explored to generate drug response profiles directly from clinical samples, leading to proof-of-concept results and raising interest in exploring this approach in clinical trials (Fig 3) . The first screening platform tested a customized library of kinase inhibitors, 71 leading to a prospective trial in relapsed acute myeloid leukemia. The Primary Blood Cancer Encyclopedia project, which integrates short-term drug testing data with transcriptome and DNA methylome analysis, strongly supported the value of phenotypic screening in hemato-oncology. 72 Some platforms are based on large viability assays for high-throughput testing [72] [73] [74] with the advantage of simplicity and lower costs, and other, more sophisticated platforms are based on automated microscopy, which can discriminate leukemia cells with the normal microenvironment at the single-cell level. 75, 76 Functional screens of ALL samples maintained on mesenchymal stromal cells identified unexpected dependencies in defined HR ALL subtypes, 77 captured response heterogeneity across ALL subtypes, efficiently discriminated patients on the basis of drug sensitivity 75, 78, 79 and detected new pathways and vulnerabilities in resistant disease. 75, [77] [78] [79] [80] New Disease Models Drug development can be accelerated using humanized mouse models with primary leukemia 81, 82 
Molecular profiling
Identification of actionable targets (types A, B, C)
Drug associations
Subset-specific treatment protocol (phase I-II trial)
Individual treatment plan 75, 77, 89, 93 and enable testing of new agents on samples from clinically representative cohorts of patients, providing survival cues and a longer window for combinatorial drug testing. Impressive results have been reported from a first trial assessing drug sensitivity in patients with refractory hematologic malignancies, using multiparametric image-based immunocytometry to distinguish the effect of drugs on malignant and normal blood cells. 76 Of 48 patients, informative results could be used for 17 who received assay-guided treatment, including two patients with BCP ALL, resulting in responses in eight patients (one with ALL). These results will stimulate the design of larger clinical studies on specific disease entities to capture the full potential of drug response profiling with the aims of avoiding unnecessary toxicity of inappropriate salvage regimens and improving responses in selected subgroups.
Functional Drug Screening for Molecularly Unclustered ALL
The usefulness of functional drug screening is being explored in patients with ALL not included in specific molecular clusters. For example BCL2-dependent ALL was identified by screening PDX models for sensitivity to BH3 mimetics, including venetoclax, 75, 77, 85, 94, 95 and drug combinations established to overcome resistance. 75, 96 Similarly, selective sensitivity to alternative RIP-1-dependent cell-death pathways (eg, necroptosis by SMAC [second mitochondrial-derived activator of caspases] mimetics) not exploited by current antileukemic agents were discovered.
80,97 PDX models have also been used to elucidate the critical dependence on altered metabolic function.
98-100 This underscores the importance of cross-referencing drug responses over many samples in a structured database to establish the effective and expected dose-response range for relevant outliers (ie, drug-sensitivity patterns not predicted by the molecular ALL subset).
NEW MANAGEMENT OPTIONS WITH IMMUNOTHERAPEUTICS
Rituximab
In BCP ALL, the expression of CD20 confers a poor prognosis. 101 Rituximab, a chimeric anti-CD20 antibody, was evaluated in combination with chemotherapy for untreated patients with Ph2 CD20+ BCP ALL. At the MD Anderson Cancer Center (MDACC), rituximab was added to the first four courses of the hyper-CVAD (cyclophosphamide, vincristine, doxorubicin) regimen. 44 The results demonstrated an improved CR duration, a lower relapse rate, and an improved OS, but only in patients younger than 60 years as compared with historical controls (70% v 38%, P , .001; and 75% v 47%, P = .003). Comparable data were produced by the German adult ALL Study Group. 45 The FrenchBelgian-Swiss Group for Research on Adult ALL evaluated the addition of rituximab in a phase III study using a pediatric-inspired regimen 13 : Patients 18 to 59 years old received 16 to 18 rituximab doses, resulting in improved 2-year EFS from 52% to 65% (P = .004) due to a decreased relapse rate with no increase in toxicity.
Blinatumomab
New antibody constructs have shown promise for R/R ALL.
102
Blinatumomab, a bispecific T-cell engager construct, received US Food and Drug Administration and European Medicines Agency approval. Blinatumomab simultaneously targets CD19 (present on most BCP ALL cells) and CD3 (present on cytotoxic T cells) and acts to bring ALL cells into proximity of T cells, which are capable of tumor eradication. In a phase II study, 38 189 adult patients with Ph2 R/R BCP ALL received blinatumomab with 43% (n = 81 of 189) of them achieving CR or CR with defective hematologic recovery, and 40% of responders able to successful transition to allogeneic HCT Importantly, 60 of 73 evaluable patients with CR (82%) achieved MRD negativity. Results were similar in the phase III trial, with a 44% CR or CR with defective hematologic recovery rate in the blinatumomab arm compared with 25% in patients receiving chemotherapy, 39 and a 76% rate compared with 48% in patients whose disease turned MRD negative. Although generally well tolerated, grade 3 or higher cytokine release syndrome (CRS) and neurologic toxicity was seen in 4.9% and 9.4% of patients, respectively. Blinatumomab was tested as a single agent in patients with R/R Ph+ ALL; it induced a CR rate of 36% associated with 88% MRD-negative status 40 and, in Ph2 MRD-positive ALL, achieved an excellent response rate of 78%, with prolonged survival, occasionally without HCT. 36, 103 Resistance mechanisms include a defective T-memory or regulator-cell response, PD1/PD-L1 overexpression, 104 and emergence of CD19-negative subclones.
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Inotuzumab Ozogamicin
Inotuzumab ozogamicin (INO) is an anti-CD22 antibody conjugated to calicheamicin; it is in late clinical development. A phase I/II study demonstrated a CR/ incomplete hematologic recovery rate of 68%, with 84% of responding patients achieving MRD negativity. 53 In a recent phase III trial, INO was superior to salvage chemotherapy for R/R ALL. Among the first 218 patients randomly assigned to treatment arm, 81% of those assigned to INO achieved CR, compared with 29% who received the standard of care, with a higher percentage of MRD-negative cases (78% v 28%; P , .001).
54 Duration of remission and OS favored INO, as confirmed by a long-term update reporting a 2-year rate of 22.8% versus 10% in standard-care group (P .001).
106 However, hepatotoxicity was more frequent in the INO group (51% v 34%), including incidence of sinusoidal obstruction syndrome (13% v , 1%). Although most of the cases occurred after HCT, sinusoidal obstruction syndrome developed in five patients (3%) receiving INO therapy alone.
107 Given the proven efficacy of this compound on these studies, INO is being combined with chemotherapy in the frontline setting. Using a mini-hyper-CVD (cyclophosphamide, vincristine, dexamethasone) regimen with INO in elderly patients, 47 of 48 evaluable patients (98%) achieved a CR/incomplete hematologic recovery (n = 35 CR), coupled with flow-cytometric MRD-negative status in 76%. Two-year progression-free survival and OS were 52% and 66%, respectively.
56,108
Chimeric Antigen Receptor T Cells Cellular immunotherapy with CD19-directed chimeric antigen receptor (CAR) T cells represents another promising approach for R/R disease. Anti-CD19 CAR T cells have been the most dose-response curves with eight datapoints after 72-hour exposure of ALL cells to a selection of drugs are shown as a heatmap (red responses in the nanomolar range; deep blue represents resistance in the 10-mM range). Two examples of individual strong activity to the SMAC mimetic birinapant and to dasatinib are provided, with validation in an extended set of ALL PDX. ALL, acute lymphoblastic leukemia; B-ALL, B-cell (or Burkitt) acute lymphoblastic leukemia; IC 50 , half maximal inhibitory concentration; MRD, minimal residual disease; MSC, mesenchymal stromal cell; NK, natural killer; PDX, patient-derived xenograft; SMAC, second mitochondrialderived activator of caspases; T-ALL, T-cell acute lymphoblastic leukemia.
(Continued).
extensively studied in trials using second-generation receptors, which comprise three components: an extracellular antigenrecognition domain derived from the single-chain variable fragment of a monoclonal antibody, an intracellular signaling domain (the CD3z chain from the T-cell receptor), and a costimulatory domain (most commonly, 4-1BB or CD28).
109-111 Initial phase I/II studies using the CTL019 construct reported a 90% CR rate in 30 patients (n = 25 children, n = 5 adults). 110 In addition, 88% of the patients who achieved a CR were MRD negative. Responses were durable, with seven relapses and 19 ongoing remissions (2 to 24 months) and with 15 patients receiving no additional therapy. High rates of CAR T-cell persistence (68%) and associated B-cell aplasia was reported at 6 months. In collaboration with Novartis, CTL019 was administered to 75 children and young adults, with 81% achieving CR and concurrent MRD-negative status. At a median follow-up of 10.6 months, 29 remained in CR. One-year EFS and OS were 50% and 76%, respectively.
60 This led to the approval of tisagenlecleucel (Kymriah; Novartis, Basel, Switzerland), the first CAR product in the United States.
The outcomes in adult patients treated with CAR T cells has been less impressive, with median EFS and OS of 6.1 months and 12.9 months, respectively.
63 CAR T cells but not natural killer cells 112 could also be effective against CNS leukemia. 113 Although anti-CD19 CAR T cells can generate rapid and impressive responses, therapy is associated with a unique set of severe adverse effects. The two major toxicities include CRS and neurotoxicity. In the CTL019 study, all patients experienced signs and symptoms of CRS, with eight of 30 patients requiring transfer to the intensive care unit. 110 Fortunately, tocilizumab, an anti-IL6 receptor antibody, was found effective and has become the mainstay of management for severe CRS, because it is well tolerated and rapidly effective in most cases. Current approaches include optimization of the CAR T-cell product in defined proportions of CD4 and CD8 T-cell subsets, development of humanized CARs, CARs with two costimulatory domains, allogeneic CARs, and CARs against other antigens such as CD22.
NEW MANAGEMENT OPTIONS IN MOLECULARLY DEFINED ALL SUBSETS
Ph+ ALL Outcome of Ph+ ALL was dramatically improved by TKIs.
114-118 Single-agent imatinib or dasatinib plus corticosteroids therapy, pioneered by the Gruppo Italiano Malattie Ematologiche dell'Adulto 114,119 induced CR virtually in all patients without risk of induction death. With TKI-chemotherapy combinations, CR rate exceeded 95% but death occurred in 2% to 7% of the cases. In a randomized trial from the French-Belgian-Swiss Group for Research on Adult ALL, 116 a combination of de-escalated chemotherapy plus TKI resulted in less induction toxicity and noninferior CR and survival results compared with standard chemotherapy plus TKI. In a MDACC study, ponatinib combined with hyper-CVAD led to an excellent 83% 2-year OS, even without HCT. 115 In elderly and/ or frail patients (median age, 68 years; range, 27 to 85 years), ponatinib monotherapy resulted in 87.5% 1-year OS, associated with a 45% molecular response rate in a Gruppo Italiano Malattie Ematologiche dell'Adulto study. 120 Postremission consolidation is still based on intensive chemotherapy (plus TKI) and HCT, when feasible. This "global" strategy led to survival rates approaching 50%, thus meaning we still need to improve. Chemotherapy-free trials with TKI-immunotherapy combinations (eg, TKI-blinatumomab) are ongoing (Clinicaltrial.gov identifier: NCT02744768) and will clarify the place of this antibody construct especially in eradicating MRD. As for other ALL subsets, MRD persistence is associated with recurrence, whereas its negativity may identify patients with favorable prognosis in whom the indication for HCT could be reconsidered to spare morbidity and mortality. 25 With these premises, relapse remains relatively frequent and is often sustained by mutations, the most deleterious being T315I. New, potentially active agents include axitinib, 73 a vascular endothelial growth factor receptor inhibitor active in T315I-mutant disease; a new TKI, danusertib 121 ; and ABL001 (asciminib), 122 a novel allosteric TKI that binds to the myristoyl pocket of ABL1, causing an inactive kinase conformation (Clinicaltrial.gov identifier: NCT02081378, a phase I trial for patients intolerant/ refractory to standard TKI). Notably, a drug-sensitivity testing platform 123 allowed the identification of axitinib as a selective inhibitor of the T315I mutation.
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As for combinatory studies, of interest is the simultaneous administration of dasatinib, ruxolitinib, and dexamethasone, which research in vitro was shown to restore cytokine dependency, inhibit STAT3 and STAT5 activation, and prevent leukemia initiating cell growth and acquisition of mutations (Clinicaltrial.gov identifier: NCT02494882), 124 and the combination of ruxolitinib with nilotinib (Clinicaltrial.gov identifier: NCT01914484). In cases with IKZF1 impairment, retinoids can induce IKZF1 re-expression, stimulate cell maturation. and restore in vitro TKI sensitivity. 125 Moreover, promoters of myelomonocytic differentiation can successfully induce Ph+ ALL cells into nonleukemic monocytes/macrophages.
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Ph-Like ALL
The Ph-like subgroup, initially identified by gene expression profiling, accounts for approximately 20% of adult BCP ALL cases, with a prevalence in AYA. These cases are characterized by a transcriptional profile similar to that of Ph+ ALL but lacking the t(9;22)/BCR-ABL1 rearrangement. [127] [128] [129] [130] Instead, the underlying genomic lesions are heterogeneous, making its recognition difficult and uneven among trials. CRLF2 rearrangements are detected in approximately 50%; lesions affecting ABL class genes (ie, ABL1, ABL2, CSF1R, PDGFRA, PDGFRB) in approximately 10%; and JAK/STAT genes (ie, JAK1-3, IL7R, and CRLF2 mutations) in , 10%. Rearrangements in other TKs and the EPOR gene are extremely rare. IKZF1 deletions occur in # 80% of cases. Patients with Ph-like ALL have a poorer outcome when compared with other BCP ALL subsets and it is not yet clear whether they should receive an HCT up front, on the basis of MRD persistence only.
128,131 Given the activated kinome profile, several groups are testing the combination of TKIs with chemotherapy. Children's Oncology Group is testing ruxolitinib in patients with CRLF2 rearrangements and/or JAK-STAT deregulation (Clinicaltrial.gov identifier: NCT02723994) or dasatinib in untreated patients (Clinicaltrial.gov identifier: NCT02883049), while MDACC is testing these drugs in pretreated patients (Clinicaltrial.gov identifier: NCT02420717) with disappointing results. 132 Other experimental jco.org approaches use a variety of inhibitors on the basis of the individual molecular profile. The pan-TKI ponatinib could be effective regardless of the underlying genetic lesion.
133
MLL-Rearranged ALL The prognosis of t(4;11)/KMT2A-AFF1+ and other MLLrearranged ALLs is poor and could be improved by new targeted approaches. MLL (ie, KMT2A) rearrangements are associated with high levels of H3K79 methylation catalyzed by the DOTL1 enzyme. Therefore, DOT1L inhibitors, particularly EPZ-5676 (pinometostat), have been tested in R/R cases (Clinicaltrial.gov identifiers: NCT02141828 and NCT01684150) in both pediatric and adult cohorts.
134 Furthermore, MLL-rearranged cases express high levels of Bcl-2, BAX, and BIM, but relatively low levels of BCL-XL and MCL-1, a mechanism directly sustained by KMT2A rearrangement on BCL2 expression and partly mediated by interaction with H3K79me2/3. As a consequence, in vitro and xenograft model studies showed that the Bcl-2 inhibitor venetoclax induces cell killing in synergy with chemotherapy. 85, 135, 136 In addition, histone deacetylase inhibitors (HDACis) can exert synergistic activity with cytarabine by repressing cytidine deaminase.
137
TCF3-Rearranged ALL TCF3-PBX1+ ALL associated with t(1;19) represents approximately one-half of the cases of the newly recognized pre-Bcell receptor (BCR)+ subset and is characterized by a favorable outcome with intensive treatment. These cases could be targeted by dasatinib because they overexpress many TKs, 138 including the BCR-dependent TK ROR1 139 and Mer TK, which correlates with risk of CNS progression, 140 by idelasib due to the high levels of PIK3CD 141 and ibrutinib via downmodulation of the pre-BCR signaling on BCL6.
98,142,143
Instead, TCF3-HLF+ ALL is a very HR subset associated with t(17;19), often with high levels of BCL2 expression recalling venetoclax as a potential therapeutic compound.
77 Drug response profiling predicted robust resistance to conventional drugs and confirmed a unique sensitivity to venetoclax. Combination therapy with dexamethasone, vincristine, and venetoclax in PDX from two patients maintained CR for up to 1 year.
77
Hypodiploid BCP ALL Hypodiploid ALL is a rare, poor prognostic subtype including near-haploid (24 to 31 chromosomes), low hypodiploid (32 to 39 chromosomes), and high hypodiploid (40 to 43 chromosomes) ALL.
144 RAS and PI3K pathways are frequently altered in nearhaploid ALL, whereas TP53 and IKZF members are often mutated in low hypodiploid ALL, pinpointing functional targeting using PI3K and PI3K/mTOR inhibitors. 144, 145 Germline mutational screening of TP53 should always be performed in these cases.
Other BCP ALL Subsets
Many other actionable deletions or mutations are emerging in BCP ALL (and sometimes TCP ALL). 127, 144, [146] [147] [148] These involve pathways affecting lymphoid development, cell cycle, regulation of transcription, lymphoid and RAS signaling, epigenetic modifications, cytokine receptors, TK expression, and the JAK/STAT phosphorylation system (Tables 3 and 4) . Focus is now on downstream members of the RAS pathway, namely the MEK and PI3K inhibitor BEZ235 (Clinicaltrial.gov identifier: NCT01756118), the allosteric MEK1/2 inhibitor selumetinib, trametinib, steroids, and FLT3 inhibitors (ie, lestaurtinib, midostaurin, and quizartinib, all being evaluated in phase I-II and III trials, respectively; Clinicaltrial. gov identifiers: NCT 00866281, NCT00557193, and NCT01411267). Among epigenetic regulators, the HDACis vorinostat and panobinostat are being investigated in phase I-II trials for R/R disease (Clinicaltrial.gov identifiers: NCT01483690, NCT01321346, and NCT01321346); however, there have been reports of toxicity. 148a JAK2 inhibitors (ruxotilinb) and Bcl-2 inhibitors might be used in cases harboring target mutations. SMAC mimetics, directly acting on apoptosis and necroptosis pathways, proteasome inhibitors, and checkpoint inhibitors, have shown in vitro activity and are being studied (Supplemental Data). The role of inhibitors of molecules involved in interaction with the marrow niche (ie, NOTCH3 and NOTCH4) is still largely undetermined 149 ; targeting SCD and SPP1 genes and proteins 150 and vascular endothelial growth factor A (with bevacizumab) could be useful against CNS leukemia. MYC rearrangements are the hallmark of B-ALL, leading to escape from cell-cycle control and a high proliferative rate. Thus, inhibition of MYC-related pathways is an attractive option for refractory disease. MYC inhibitors JQ1 and THZ1 target MYC/ MAX heterodimerization and CDK7 (THZ1), whereas dependency of MYC activation on multiple enhancers and so-called superenhancers, such as a BET proteins and PI3K, are targeted by mTOR or HDACis, Aurora kinase A and B, and other BET inhibitors (namely, I-BET 151, GSK525762, and CPI-0610).
152 New phase I trials are underway.
TCP ALL
TCP ALL accounts for approximately 25% of ALL cases and is further classified according to maturation stage (ie, early-, cortical-, and mature T). With modern pediatric-based regimens adopting MRD or risk-oriented intensification, outcome of TCP ALL may be excellent and superior to that of BCP ALL. Among actionable molecular lesions, 153 the most frequent is NOTCH1 mutation. NOTCH1 and the strictly associated g-secretase inhibitors were tested in late-stage disease, with some responses of short duration and considerable gut toxicity. 154 The best study reported one CR and an overall 32% response rate in 25 patients with relapsed disease.
155 Theoretically, targeting NOTCH1-related overexpression of chemokine receptor CCR7 and its ligand CCL19 could reduce the risk of CNS disease.
156 Many other targeting agents are being investigated, often in combination, like g-secretase inhibitors and AKT inhibitors to revert glucocorticoid resistance [157] [158] [159] (Fig 2; Tables 3 and 4) . Moreover, induction of T-cell receptor signaling led to apoptosis mimicking thymic negative selection, 160 and targeting contact structures with the marrow microenvironment (ie, CXCR4, CXCL12) reduces proliferation and the propagation potential of leukemic stem cells. 161, 162 Notably, PDX and drug screening models identified a subset of refractory T-ALL responsive to dasatinib in a nanomolar range, correlating with strong responses in vivo after resistance to multiple other treatments. 75 
ETP ALL
This peculiar diagnostic subset (with weak or absent CD5 expression and mixed T-lympho/myeloid phenotype and genotype) is associated with poor outcome unless treated with very intensive MRD-based chemotherapy or HCT in first CR.
163 ETP ALL is characterized by abnormalities typically observed in myeloid disorders, including mutations in RUNX1, ETV6, GATA3, IDH1, IDH2, DNMT3A, 164, 165 and the JAK/STAT pathway. In an experimental PDX model, ETP ALL was exquisitely sensitive to ruxolitinib, which abrogated IL-7-induced STAT5 phosphorylation. 166 Furthermore, FLT3 inhibitors might be considered, because mutations are detected in approximately 35% of cases.
167
FUTURE DIRECTIONS
We are entering an intensive phase of clinical investigations with new agents. To take advantage of these new treatment options, we will have to gradually shift from R/R ALL to the frontline setting, where treatment resistance is less likely to occur. 168 We will certainly need to develop solutions to integrate functional and genomic data for reference bioinformatics tools supporting clinical decisions, in accordance with studies in patients with cancer including acute myeloid leukemia and childhood ALL. [169] [170] [171] For the exploration of individualized or subset-specific treatment forms, it will be crucial to design prospective clinical studies with modular elements to evaluate optimal strategies for chemotherapy, 172 immunotherapy, and combinations of molecularly targeted drugs and synergistic drug pairs, 74, 173 and detect activity in the early clinical trials more rapidly to pilot subsequent therapeutic developments.
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